NABNEC: A Randomised Phase II Study Of Nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1102018

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients with advanced neuroendocrine carcinomas (NEC) have one of the poorest cancer outcomes. So far, no randomised trials have been done to confirm NEC treatment. Current NEC chemotherapy is etoposide & carboplatin (EC), based on lung cancer trials. The NABNEC study will use a new drug, nab-paclitaxel, with carboplatin or EC, collect PET scan, tumour & blood samples result to help understand how treatment works and to ultimately improve NEC patients’ health and progress future research.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $1,393,083.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chemotherapy treatment effects | gastrointestinal | neuroendocrine | pancreatic cancer | randomised controlled trial (RCT)

Related Links